Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis

Simple item page
dc.contributor.authorÖzgün, Gonca
dc.contributor.buuauthorYalçınkaya, Ulviye
dc.contributor.buuauthorUğraş, Nesrin
dc.contributor.buuauthorOcakoğlu, Gökhan
dc.contributor.buuauthorDeligönül, Adem
dc.contributor.buuauthorÇetintaş, Sbel Kahraman
dc.contributor.buuauthorBilgen, Muhammed Sadık
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Cerrahi Patoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Ortopedi Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-5180-2021tr_TR
dc.contributor.researcheridAAA-7047-2020tr_TR
dc.contributor.researcheridAAH-8924-2021tr_TR
dc.contributor.researcheridAAH-2716-2021tr_TR
dc.contributor.scopusid6508300295tr_TR
dc.contributor.scopusid55386535600tr_TR
dc.contributor.scopusid15832295800tr_TR
dc.contributor.scopusid37088030300tr_TR
dc.contributor.scopusid6505881756tr_TR
dc.contributor.scopusid35723877700tr_TR
dc.date.accessioned2023-01-27T07:50:08Z
dc.date.available2023-01-27T07:50:08Z
dc.date.issued2017
dc.description.abstractSynovial sarcoma (SS) is a type of soft-tissue sarcoma, often linked to poor survival. Although overexpression of enhancer of zeste homologue 2 (EZH2) has been associated with poor prognosis in different tumors, a few studies investigated this link in SS. Here, we analyzed the relationship between EZH2 expression and prognostic factors in SS. We included 29 patients with SS. Immunostaining of EZH2 was performed with (D2C9) XP (TM) Rabbit mAb antibody, and the results were classified as low EZH2 expression (negative or weak expression) and high EZH2 expression category (moderate or strong expression). Analysis of survival in relation to prognostic factors was performed with Kaplan-Meier survival curves and Cox proportional hazard regression analysis. Our sample included 19/29 female and 10/29 male patients, with age range 16-63 years. The tumor diameter ranged from 2 to 15 cm. Necrosis was observed in 15/29 cases. Sixteen cases had > 10 mitoses per 50 high-power fields (HPFs). Out of 29 cases, 14 showed low and 15 had high EZH(2) expression. Statistically significant results were obtained for the association between the presence of metastasis and necrosis (p = 0.042), high EZH2 expression and distant metastasis (p = 0.018), high EZH2 expression and necrosis (p = 0.016), and high EZH2 expression and the tumor size > 5 cm versus tumor size <= 5 cm (p = 0.014). Patients with all of the following: the tumor size <= 5 cm, low EZH2 expression, and without necrosis and distant metastasis had significantly longer survival time. Our results are consistent with previous studies, suggesting that EZH(2) overexpression is an indicator of poor prognosis in SS.en_US
dc.identifier.citationYalçınkaya, U. vd. (2017). ''Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis''. Bosnian Journal of Basic Medical Sciences, 17(4), 302-308.en_US
dc.identifier.endpage308tr_TR
dc.identifier.issn1512-8601
dc.identifier.issue4tr_TR
dc.identifier.pubmed28738014tr_TR
dc.identifier.scopus2-s2.0-85036570981tr_TR
dc.identifier.startpage302tr_TR
dc.identifier.urihttps://doi.org/10.17305/bjbms.2017.1938
dc.identifier.uri1840-4812
dc.identifier.urihttps://www.bjbms.org/ojs/index.php/bjbms/article/view/1938
dc.identifier.urihttp://hdl.handle.net/11452/30687
dc.identifier.volume17tr_TR
dc.identifier.wos000416993000004tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherAssoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevoen_US
dc.relation.bapHDP (T)-2013/2tr_TR
dc.relation.collaborationYurt içitr_TR
dc.relation.journalBosnian Journal of Basic Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectResearch & experimental medicineen_US
dc.subjectEnhancer of zeste homologue 2 (EZH2)en_US
dc.subjectImmunohistochemistryen_US
dc.subjectPrognostic factorsen_US
dc.subjectSurvival analysisen_US
dc.subjectSynovial sarcomaen_US
dc.subjectSsx-fusion-typeen_US
dc.subjectRetrospective analysisen_US
dc.subjectSoft-tissueen_US
dc.subjectCanceren_US
dc.subjectMulticenteren_US
dc.subjectChildrenen_US
dc.subjectRisken_US
dc.subjectProliferationen_US
dc.subjectAdolescentsen_US
dc.subjectProgressionen_US
dc.subject.emtreeEZH2 protein, humanen_US
dc.subject.emtreeTranscription factor EZH2en_US
dc.subject.emtreeTumor markeren_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeBiosynthesisen_US
dc.subject.emtreeBlooden_US
dc.subject.emtreeCancer stagingen_US
dc.subject.emtreeDisease free survivalen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGene expression regulationen_US
dc.subject.emtreeGeneticsen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeImmunohistochemistryen_US
dc.subject.emtreeKaplan meier methoden_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMetastasisen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeNecrosisen_US
dc.subject.emtreePathologyen_US
dc.subject.emtreePredictive valueen_US
dc.subject.emtreePrognosisen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeSynovial sarcomaen_US
dc.subject.emtreeYoung adulten_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshBiomarkersen_US
dc.subject.meshTumoren_US
dc.subject.meshDisease-free survivalen_US
dc.subject.meshEnhancer of zeste homolog 2 proteinen_US
dc.subject.meshFemaleen_US
dc.subject.meshGene expression regulationen_US
dc.subject.meshNeoplasticen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshKaplan-meier estimateen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshNeoplasm metastasisen_US
dc.subject.meshNeoplasm stagingen_US
dc.subject.meshPredictive value of testsen_US
dc.subject.meshPrognosisen_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshSarcoma, synovialen_US
dc.subject.meshYoung adulten_US
dc.subject.meshNecrosisen_US
dc.subject.scopusSynovial Sarcoma; Cancer; Mucin-1en_US
dc.subject.wosMedicine, research & experimentalen_US
dc.titleEnhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosisen_US
dc.typeArticle
dc.wos.quartileQ4en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Yalçınkaya_vd_2017.pdf
Size:
1.53 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus